Leukoreduced blood components: Advantages and strategies for its implementation in developing countries

Area of Science:

• Transfusion Medicine
• Hematology
• Immunology

Background:

• Leukocyte removal from blood products is crucial for minimizing febrile nonhemolytic transfusion reactions.
• It also helps prevent HLA alloimmunization and platelet refractoriness in multitransfused patients.
• Preventing transmission of leukotropic viruses like EBV and CMV is another significant benefit.

Purpose of the Study:

• To review the current literature on leukocyte filtration (leukofiltration) in blood products.
• To discuss the advantages and disadvantages of leukofilteration.
• To explore the implementation scope of leukofilteration in cost-constrained settings.

Main Methods:

• Review of current scientific literature on leukofilteration.
• Analysis of the efficacy of different generations of leukofilters.
• Evaluation of apheresis devices for leukocyte removal.

Main Results:

• Leukocyte removal below 5 x 10^6 per blood component aids in preventing alloimmunization.
• Third and fourth-generation leukofilters offer the best leucoreduction.
• Apheresis devices also provide effective leukocyte removal.

Conclusions:

• Leukocyte reduction is essential for managing hemato-oncology patients requiring frequent transfusions.
• Advanced leukofilters and apheresis devices are effective tools for achieving desired leukocyte thresholds.
• The implementation of leukofilteration needs consideration within cost-constrained healthcare environments.